341 related articles for article (PubMed ID: 29285544)
1. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
Prasad V; Kaestner V; Mailankody S
JAMA Oncol; 2018 Feb; 4(2):157-158. PubMed ID: 29285544
[No Abstract] [Full Text] [Related]
2. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
Lemery S; Keegan P; Pazdur R
N Engl J Med; 2017 Oct; 377(15):1409-1412. PubMed ID: 29020592
[No Abstract] [Full Text] [Related]
3. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Marcus L; Lemery SJ; Keegan P; Pazdur R
Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
[TBL] [Abstract][Full Text] [Related]
5. Teenage colorectal polyposis and cancer may be caused by constitutional mismatch repair deficiency (CMMRD).
Soplepmann J; Laidre P
Acta Oncol; 2016 Dec; 55(12):1503-1505. PubMed ID: 27723366
[No Abstract] [Full Text] [Related]
6. Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome.
Galuppini F; Opocher E; Tabori U; Mammi I; Edwards M; Campbell B; Kelly J; Viel A; Quaia M; Rivieri F; D'Avella D; Arcella A; Giangaspero F; Fassan M; Gardiman MP
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):233-239. PubMed ID: 29130549
[No Abstract] [Full Text] [Related]
7. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of mismatch repair deficiency in sarcomas.
Doyle LA; Nowak JA; Nathenson MJ; Thornton K; Wagner AJ; Johnson JM; Albrayak A; George S; Sholl LM
Mod Pathol; 2019 Jul; 32(7):977-987. PubMed ID: 30765880
[TBL] [Abstract][Full Text] [Related]
9. MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer.
Aguiar PN; Tadokoro H; Forones NM; de Mello RA
Immunotherapy; 2015; 7(11):1133-4. PubMed ID: 26568256
[No Abstract] [Full Text] [Related]
10. Paediatric systemic lupus erythematosus as a manifestation of constitutional mismatch repair deficiency.
Toledano H; Orenstein N; Sofrin E; Ruhrman-Shahar N; Amarilyo G; Basel-Salmon L; Shuldiner AR; Smirin-Yosef P; Aronson M; Al-Tarrah H; Bazak L; Gonzaga-Jauregui C; Tabori U; Wimmer K; Goldberg Y
J Med Genet; 2020 Jul; 57(7):505-508. PubMed ID: 31501241
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
Goeppert B; Roessler S; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil A; Czink E; Köhler B; Springfeld C; Pfeiffenberger J; Rupp C; Weiss KH; Schirmacher P; von Knebel Doeberitz M; Kloor M
Br J Cancer; 2019 Jan; 120(1):109-114. PubMed ID: 30377340
[TBL] [Abstract][Full Text] [Related]
12. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells.
Guillotin D; Austin P; Begum R; Freitas MO; Merve A; Brend T; Short S; Marino S; Martin SA
Clin Cancer Res; 2017 Jun; 23(11):2880-2890. PubMed ID: 27913567
[No Abstract] [Full Text] [Related]
13. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab.
Caccese M; Barbot M; Ceccato F; Padovan M; Gardiman MP; Fassan M; Denaro L; Emanuelli E; D'Avella D; Scaroni C; Zagonel V; Lombardi G
Anticancer Drugs; 2020 Feb; 31(2):199-204. PubMed ID: 31702999
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
[TBL] [Abstract][Full Text] [Related]
15. Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
Casey RT; Giger O; Seetho I; Marker A; Pitfield D; Boyle LH; Gurnell M; Shaw A; Tischkowitz M; Maher ER; Chatterjee VK; Janowitz T; Mells G; Corrie P; Challis BG
Semin Oncol; 2018 Jun; 45(3):151-155. PubMed ID: 30262398
[TBL] [Abstract][Full Text] [Related]
16. Cutting-edge cancer drug hobbled by diagnostic test confusion.
Ledford H
Nature; 2018 Apr; 556(7700):161-162. PubMed ID: 29636574
[No Abstract] [Full Text] [Related]
17. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
18. Transmembrane Protease TMPRSS4 Promotes the Formation and Development of Mismatch Repair Deficient Colon Cancer Liver Metastasis.
Yang YS; Wen D; Zhao XF
Bull Exp Biol Med; 2021 May; 171(2):242-246. PubMed ID: 34173918
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair deficiency predicts benefit of anti-PD-1 therapy.
Lau E
Lancet Oncol; 2015 Jul; 16(7):e319. PubMed ID: 26062774
[No Abstract] [Full Text] [Related]
20. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.
Solomon BL; Garrido-Laguna I
Future Oncol; 2018 Apr; 14(10):947-962. PubMed ID: 29542354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
